Bausch Health Closes 2024 with Strong Q4 Performance
On Wednesday, February 19, Bausch Health held its Fourth Quarter 2024 Earnings Call Conference Call, where the company's CEO, Thomas Appio, and CFO, JJ Charhon, discussed the company's latest results.
The strong fourth quarter performance marked the seventh consecutive quarter of revenue and adjusted EBITDA growth for the company. According to Thomas Appio, this achievement is a testament to their "strong operational execution, disciplined approach, and relentless focus on value creation."
During the call, the CEO highlighted the company's progress in 2024, stating that they made "tremendous progress as a company" and are proud of what the Bausch Health team accomplished. The momentum heading into 2025 is a key takeaway from this call.
The financial results for Q4 2024 show revenues increasing by 4% on a reported basis and 7% on an organic basis compared to the same period last year, with strong organic growth in Salix and Solta segments. The full-year revenue increased by 5% on a reported basis and 6% on an organic basis.
Adjusted EBITDA for Bausch Health, excluding Bausch + Lomb, saw a 7% increase in the fourth quarter of 2024 compared to the prior period. For the full year of 2024, all four segments delivered revenue and segment profit growth, demonstrating the company's ability to drive performance across its diverse businesses.
The success was also reflected in strong cash flow from operations for the company in 2024, with Bausch Health generating approximately $1.3 billion in adjusted operating cash flow for the full year.
Looking ahead to 2025, the company is focused on driving value through three fundamental pillars: enhancing the value of operational assets, driving innovation and execution, and maximizing growth potential; actively exploring ways to unlock the full value of their Bausch + Lomb equity stake; and continuing to execute against the guidance provided.
